Seminars in Oncology
Volume 33, Issue 1 , Pages 68-73 , February 2006

Renal Toxicities of Chemotherapy

  • Maja J.A. de Jonge

      Affiliations

    • Corresponding Author InformationAddress correspondence to Maja J.A. de Jonge, Erasmus University Medical Center/ Daniel den Hoed Cancer Center, Department of Medical Oncology, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    • ,
  • Jaap Verweij

References 

  1. Rahn KH , Heindenreich S , Brückner D . How to assess glomerular function and damage in humans . J Hypertens . 1999;17:309–317
  2. Doolan PD , Alpen EL , Theil GB . A clinical appraisal of the plasma concentration and endogenous clearance of creatinine . Am J Med . 1962;65–79
  3. Poole SG , Dooley MJ , Rischin D . A comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99m DTPA clearance) in cancer patients . Ann Oncol . 2002;13:949–955
  4. Daugaard G , Abildgaard U . Cisplatin nephrotoxicity . Cancer Chemother Pharmacol . 1989;25:1–9
  5. Lau AH . Apoptosis induced by cisplatin nephrotoxic injury . Kidney Int . 1999;56:1295–1298
  6. Arany I , Safirstein RL . Cisplatin nephrotoxicity . Semin Nephrol . 2003;23:460–464
  7. Kroning R , Katz D , Lichtenstein AK , et al.   Differential effects of cisplatin in proximal and distal renal tubule epithelial cell lines . Br J Cancer . 1999;79:293–299
  8. Osanto S , Bukman A , Van Hoek F , et al.   Long-term effects of chemotherapy in patients with testicular cancer . J Clin Oncol . 1992;10:574–579
  9. Kintzel PE . Anticancer drug-induced kidney disorders . Drug Saf . 2001;24:19–38
  10. Hutchison FN , Perez EA , Gandara DR , et al.   Renal salt wasting in patients treated with cisplatin . Ann Intern Med . 1985;108:21–25
  11. Bell DR , Woods RL , Levi JA . cis-Diamminedichloroplatinum-induced hypomagnesemia and renal magnesium wasting . Eur J Cancer Clin Oncol . 1985;21:287–290
  12. Watson PR , Guthrie TH , Caruana RJ . Cisplatin-associated hemolytic-uremic syndrome . Cancer . 1989;64:1400–1403
  13. Hayes DM , Cvitkovic E , Golbey RB , et al.   High dose cisplatinum diammine dichloride. Amelioration of renal toxicity by mannitol diuresis . Cancer . 1977;39:1372–1381
  14. Forrester SD , Fallin EA , Saunders GK , et al.   Prevention of cisplatin-induced nephrotoxicosis in dogs, using hypertonic saline solution as the vehicle of administration . Am J Vet Res . 1993;54:2175–2178
  15. Ozols RF , Corden BJ , Jacob J , et al.   High-dose cisplatin in hypertonic saline . Ann Intern Med . 1984;100:19–24
  16. Aamdal S , Fodstad Ø , Kaalhus O , et al.   Reduced antineoplastic activity in mice of cisplatin administered with high salt concentration in the vehicle . J Natl Cancer Inst . 1984;73:743–752
  17. Hanigan MH , Deng M , Zhang L , et al.   A small increase in the Na ion concentration inhibits cisplatin toxicity in culture . Proc Am Assoc Cancer Res . 2002;43:423–424 (abstr 2106)
  18. Osman AM , El-Sayed EM , El-Demerdash E , et al.   Prevention of cisplatin-induced nephrotoxicity by methimazole . Pharmacol Res . 2000;41:115–121
  19. Mishima K , Hidaka S , Takamura N , et al.   Protection against cis-diamminedichloroplatinum-induced nephrotoxicity by 2,3-dimercaptosuccinic acid in rats . Renal Fail . 1999;21:593–602
  20. Nakamura T , Kokuryo T , Hashimoto Y , et al.   Effects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats . J Pharm Pharmacol . 1999;51:227–232
  21. Greggi Antunes LM , Darin JD , Bianchi MD . Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats (A dose-dependent study) . Pharmacol Res . 2000;41:405–411
  22. Saad SY , Najjar TA , Al-Sohaibani MO . The effect of rebamipide on cisplatin-induced nephrotoxicity in rats . Pharmacol Res . 2000;42:81–86
  23. Somani SM , Husain K , Whitworth C , et al.   Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats (Antioxidant defense system) . Pharmacol Toxicol . 2000;86:234–241
  24. Naziroǧlu M , Karaoǧlu A , Aksoy AO . Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal liver and lens tissues in rats . Toxicology . 2004;195:221–230
  25. Berry JM , Jacobs C , Sikic B , et al.   Modification of cisplatin toxicity with diethyldithiocarbamate . J Clin Oncol . 1990;8:1585–1590
  26. Kemp G , Rose P , Lurain J , et al.   Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities (Results of a randomized control trial in patients with advanced ovarian cancer) . J Clin Oncol . 1996;14:2101–2112
  27. Planting AS , Catimel G , De Mulder PH , et al.   Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer (EORTC Head and Neck Cooperative Group) . Ann Oncol . 1999;10:693–700
  28. Hardy JR , Tan S , Fryatt I , et al.   How nephrotoxic is carboplatin? . Br J Cancer . 1990;61:644
  29. Cassidy J , Misset J-L . Oxaliplatin-related side effects (Characteristics and management) . Semin Oncol . 2002;29:11–20
  30. Stillwell TJ , Benson RC . Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients . Cancer . 1988;61:451–457
  31. Zalupski M , Baker LH . Ifosfamide . J Natl Cancer Inst . 1988;80:556–566
  32. Kerbush T , De Kraker J , Keizer J , et al.   Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites . Clin Pharmacokinet . 2001;40:41–62
  33. Hows JM , Mehta A , Ward L , et al.   Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation (A prospective randomised study) . Br J Cancer . 1984;50:753–756
  34. Shepherd JD , Pringle LE , Barnett MJ , et al.   Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation . J Clin Oncol . 1991;9:2016–2020
  35. Goren MP , Houle JM , Bush DA , et al.   Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects . Clin Cancer Res . 1998;4:2313–2320
  36. Skinner R , Sharkey IM , Pearson AD , et al.   Ifosfamide, mesna, and nephrotoxicity in children . J Clin Oncol . 1993;11:173–190
  37. McCune JS , Friedman DL , Schuetze S , et al.   Influence of age upon ifosfamide-induced nephrotoxicity . Pediatr Blood Cancer . 2004;42:427–432
  38. Skinner R . Chronic ifosfamide nephrotoxicity in children . Med Pediatr Oncol . 2003;41:190–197
  39. Langer T , Stohr LT , Bielack S , et al.   Late effects surveillance system for sarcoma patients . 2004;42:373–379
  40. Schacht RG , Feiner HD , Gallo GR , et al.   Nephrotoxicity of nitrosoureas . Cancer . 1981;48:1328–1334
  41. Harmon WE , Cohen HJ , Schneeberger EE , et al.   Chronic renal failure in children treated with methyl CCNU . N Engl J Med . 1979;300:1200–1203
  42. Cantrell JE , Phillips TM , Schein PS . Carcinoma-associated hemolytic-uremic syndrome (A complication of mitomycin C chemotherapy) . J Clin Oncol . 1985;3:723–734
  43. Snyder HW , Mittelman A , Oral A , et al.   Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma . Cancer . 1993;71:1882–1892
  44. Lhotta K , Kühr T , Rumpelt H , et al.   Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy . Am J Nephrol . 1999;19:590–593
  45. Abelson HT , Fosburg MT , Beardsley P , et al.   Methotrexate-induced renal impairment (clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine) . J Clin Oncol . 1983;1:208–216
  46. Widemann BC , Balis FM , Kempf-Bielack B , et al.   High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma . Cancer . 2004;100:2222–2232
  47. Margolis J , Grever MR . Pentostatin (Nipent) (A review of potential toxicity and its management) . Semin Oncol . 2000;27:9–14
  48. Tsimberidou A-M , Giles F , Duvic M , et al.   Phase II study of pentostatin in advanced T-cell lymphoid malignancies . Cancer . 2004;100:342–349
  49. Cutting HO . Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy . Am J Med . 1971;51:269–271

PII: S0093-7754(05)00432-X

doi: 10.1053/j.seminoncol.2005.11.011

Seminars in Oncology
Volume 33, Issue 1 , Pages 68-73 , February 2006

Article Tools

* Image Usage & Resolution